Strategy or Tactics—What Should be the Focus for Medtech in 2022?
Successful business executives know strategy is important, but they also understand the most effective plans focus on winning methods. So what should be the focus for Medtech in 2022? Strategy or tactics?
What’s Your China Strategy?
The post-pandemic 2022 may be a new strategic inflection point for many organizations relative to their China strategy. This leads to the question for MedTech businesses: What is your China strategy going forward?
Who's Your Buyer? A Look Into The Most Common Types of Buyers In A Business Acquisition - A Podcast
A discussion on the most common, active types of buyers we've been seeing in this market when it comes to business acquisition. Medworld Advisors Managing Director and Co-Founder, Dave Sheppard, brings great insights about what each different type of buyer is looking for in terms of price, terms, transaction timelines & more.
How to Use Supply Chain Challenges to Win New Business
Given the scramble to address supply chain challenges, this year might be an ideal time for MedTech firms to re-evaluate ways to generate new business.
Ukraine - MedWorld Advisors Statement
MedWorld Advisors statement on the situation in Ukraine.
Want to end high inflation in 2022?
Uniting to end the labor shortage will slow down MedTech Industry price increases.
MedTech Trends in 2022: Headwinds and Tailwinds
The new year begins amid a dramatically different medtech environment than 2021. Although the industry’s future remains bright, a unique set of challenges—or headwinds—awaits the sector in 2022. Fortunately, those headwinds can be conquered by equally unique opportunities, or tailwinds.
Ortoma Signs Agreement with J&J K.K. for Exclusive Distribution Rights in Japan, Facilitated by MedWorld Advisors
Ortoma signs agreement with Johnson & Johnson K.K. for exclusive distribution rights in Japan of the Ortoma Treatment Solution for hip surgery. It is the first agreement that the company executes with a global strategic partner. The agreement allows for the possibility to expand the partnership to other global markets.
Preparing for 2022
As we are now moving into 2022, it appears that while 2021 was less volatile than 2020, it certainly has had its own drama which will impact us as we head into a new year. Here are some of the high impact areas affecting the healthcare industry for 2022.
Common Mistakes Seller’s Make When Trying to Make Their Exit
Ready to sell? What are some of the common mistakes seller’s often make when trying make their exit? Do you know what they are? And more importantly how can you avoid them?
Deja-vu? MedTech M&A Moving Into 2022
Another new variant is coming to life and the uncertainty that has become commonplace in our lives is once again at center stage. What does this uncertainty mean for your business, the Healthcare industry, and mergers and acquisitions in general?
What’s Next for Medtech’s Top Companies 2022?
It’s an ideal time to reflect upon the 2021 performance of MedTech’s largest OEMs and portend their growth prospects for the coming year.
Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID
Revelation Biosciences Inc. engages partnering advisor, MedWorld Advisors, to optimize value of the company’s diagnostic tool, REVID
Orthopedic Industry Insights and Reflections
We’ve attended the AAOS Annual Meeting many times over the years to gain insights into this $50 billion market (estimated). The meeting has provided valuable data about orthopedic industry trends and its impacts on other healthcare market segments. Clearly, orthopedics is a sector that cannot and should not be ignored.
Are We in an M&A Bubble?
Are we in an M&A bubble? And if we are, how will this affect transaction multiples moving into 2022 and beyond? From our recent webinar series MedTech M&A: A Financial Buyer's Perspective, Managing Director - Middle Markets Daniel Sheppard asks this very question to our panel of industry professionals.
MedTech Co-opetition is Maturing in a Positive Way
In 2021, the need for collaboration on a B2B level has never been more apparent, which is great for our industry. The more that our medtech industry opens up and works together (even while competing) the more growth it creates for us all. It also creates possibilities for more efficiency in our healthcare system.
MedWorld Advisors Once Again Listed to Axial’s Top 20 Lower Middle Market Investment Banks
MedWorld Advisors once again named to Axial’s Top 20 Lower Middle Market Investment Banks for Q3 2021.
Contact us.
We love what we do as we partner with our clients to bring them success. There are often many approaches to achieve your goals and will help you be successful. The best thing about our services is that YOU decide what YOU want to engage us for.
Connect with us for further details.
contact@medworldadvisors.com
(805) 441-0962
153 Summer Street
Andover, MA 01810